Orion OYJ (OTCMKTS:ORINY) Shares Gap Up – Should You Buy?

Posted by George Bondi on Nov 1st, 2026

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY – Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $54.00, but opened at $58.05. Orion OYJ shares last traded at $58.05, with a volume of 318 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Orion OYJ from a “hold” rating to a “strong-buy” rating in a report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

View Our Latest Stock Analysis on Orion OYJ

Orion OYJ Trading Up 3.4%

The business has a 50 day simple moving average of $47.94 and a two-hundred day simple moving average of $41.63. The company has a current ratio of 2.64, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The stock has a market cap of $16.41 billion, a price-to-earnings ratio of 21.46 and a beta of 0.07.

Orion OYJ (OTCMKTS:ORINY – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter. The company had revenue of $623.96 million for the quarter. Orion OYJ had a return on equity of 54.09% and a net margin of 30.25%.

Orion OYJ Company Profile

(Get Free Report)

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.